Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Asthma is one of the most common chronic diseases of childhood. Allergen sensitization and high frequencies of comorbid allergic diseases are characteristic of severe asthma in children. Omalizumab, an anti-IgE mAb, is the first targeted biologic therapeutic approved for the treatment of moderate-to-severe persistent allergic asthma (AA) that remains uncontrolled despite high-dose inhaled corticosteroids plus other controller medications. Since its initial licensing for use in adults and adolescents 12 years of age and older, the clinical efficacy, safety, and tolerability of omalizumab have been demonstrated in several published clinical trials in children aged 6 to less than 12 years with moderate-to-severe AA. These studies supported the approval of the pediatric indication (use in children aged ≥6 years) by the European Medicines Agency in 2009 and the US Food and Drug Administration in 2016. After this most recent change in licensing, we review the outcomes from clinical trials in children with persistent AA receiving omalizumab therapy and observational studies from the past 7 years of clinical experience in Europe. Data sources were identified by using PubMed in 2016. Guidelines and management recommendations and materials from the recent US Food and Drug Administration's Pediatric Advisory Committee meeting are also reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
A large-scale, consortium-based genomewide association study of asthma
Moffatt, M. F., Gut, I. G., Demenais, F., Strachan, D. P., Bouzigon, E., Heath, S., von Mutius, E., Farrall, M., Lathrop, M., & Cookson, W. O. C. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0906312 · Cited by 1,818
Asthma prevalence, health care use, and mortality: United States, 2005-2009.
Akinbami, L. J., Moorman, J. E., & Liu, X. (2011) · PubMed · Cited by 946
Moore, W. C., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Ameredes, B. T., Bacharier, L., Calhoun, W. J., Castro, M., Chung, K. F., Clark, M. P., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.11.639 · Cited by 929
Self-citationRandomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Self-citationMacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Djukanović, R., Wilson, S. J., Kraft, M., Jarjour, N. N., Steel, M., Chung, K. F., Bao, W., Fowler-Taylor, A., Matthews, J., Busse, W. W., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1651oc · Cited by 646
Self-citationTeach, S. J., Gill, M. A., Togias, A., Sorkness, C. A., Arbes, S. J., Calatroni, A., Wildfire, J. J., Gergen, P. J., Cohen, R. T., Pongracic, J. A., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.09.008 · Cited by 537
Self-citation
Cited by
Advances in understanding and reducing the burden of severe asthma in children
Pijnenburg, M. W., & Fleming, L. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30399-4 · Cited by 159
Metadata
- Authors
- Chipps, B. E., Lanier, B., Milgrom, H., Deschildre, A., Hedlin, G., Szefler, S. J., Kattan, M., Kianifard, F., Ortiz, B., Haselkorn, T., Iqbal, A., Rosén, K., Trzaskoma, B., & Busse, W. W.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 139
- Issue
- 5
- Pages
- 1431-1444
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2610654869
- Cited by
- 160
- References
- 49
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.